Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in Recurrent or Progressive IDH-Wild Type Glioma With FGFR-TACC Gene Fusion
NCT05859334Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erdafitinib in glioma, sponsored by National Cancer Institute. Started Jan 2024; status: active, not recruiting.
02
Drugs
erdafitinib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05859334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05859334.